Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Inhalation Sciences assignment in the FORMAMP project on antibiotic resistance is extended by 1,2 MSEK.

Antibiotic resistance is one of the most pressing health concerns on the planet. The EU research project FORMAMP is exploring ways of using Antimicrobial Peptides (AMPs) combined with other nanoformulation strategies, to prevent it. Inhalation Sciences has been contracted to carry out an additional series of studies for the project, extending its role and research revenues.Inhalation Sciences (ISAB) is being contracted to carry out an additional series of studies during 2017 aiming at characterizing silica particles and assess their potential as an inhaled formulation. The extended research

MOBERG PHARMA’S NOMINATION COMMITTEE APPOINTED

STOCKHOLM, November 10th, 2017 - In accordance with the resolution of the Annual General Meeting on May 18, 2017, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of

Interim Report (January - September 2017)

January - September 2017• Net sales amounted to SEK 1,361.5 million (1,266.9), a revenue growth of 7.5 percent. Adjusted for  acquisitions and FX, the organic revenue growth amounted to 1.7 percent.• Operating profit before depreciation and amortization (EBITDA) amounted to SEK 245.7 million  (264.2), corresponding to an EBITDA margin of 18.0 percent (20.8).• Net financial income/expense includes net foreign exchange differences of SEK -23.7 million (19.8).• Profit for the period amounted to SEK 49.3 million (63.9).• Earnings per share after dilution amounted to SEK 0.18 (0.22)

Immunovia Interim report, January-September 2017

“The important prospective studies for the pancreas test within the diabetes group (“PANDIA-1”) and the early symptoms group (“PANSYM-1”) have in discussions with clinical partners made progress for both PANDIA-1 and PANSYM-1. At the end of October, collection of blood samples began from patients with early symptoms at University College London Hospital. This was a very significant milestone for PANSYM-1. The retrospective, diabetes risk-group study based on the biobank from Region Skåne is also now under way.”“We are working intensively to industrialize IMMray™ PanCan–d in order to reach

Rottneros’ Nomination Committee and 2018 AGM

Rottneros’ Annual General Meeting (AGM) will be held on Wednesday, May 16, 2018 in Sunne. Nomination Committee has been appointed.In accordance with the guidelines decided at Rottneros’ 2017 AGM, the Nomination Committee has been appointed for the 2018 AGM. The Nomination Committee comprises: · Olle Grundberg, appointed by Arctic Paper S.A · Stefan Sundh, appointed by PROAD AB · Per Lundeen, Chairman of Rottneros AB The Nomination Committee has appointed Olle Grundberg as its chairman. The Nomination Committee's tasks are to, before the 2018 AGM, prepare and present

INTERIM REPORT 1 JULY – 30 SEPTEMBER 2017

Third quarter 2017, compared to 2016, Group» 50% growth in orders for Episealer® knee implants during the quarter with 42 (28) approved orders. Invoicing taking place at delivery during both Q3 and Q4 2017» Group net sales increased by 1% to SEK 520,284 (516,641)» Other operating income amounted to SEK 97,716 (–)» Loss before tax amounted to SEK –13,518,593 (–15,042,517)» Earnings per share (weighted average) amounted to SEK –0.45 (–0.79)  Significant events during the third quarter» 100 patient multi-center study of the Episealer® knee implant fully recruited» Episurf

Medivir appoints Christina Herder as Executive Vice President Strategic Business Development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today the appointment of Christina Herder, as Executive Vice President, Strategic Business Development effective December 14, 2017. Christina will report to CEO Christine Lind and will join Medivir’s executive management team.The addition of Christina at Medivir fills an important role focusing in the near-term on out-licensing of Medivir’s projects that could benefit from the capabilities of a partner, whether at late stages of clinical development or early stages of research. Christina will also be responsible for leading

Stillfront Group AB: Babil Games launches Nida Harb 3: Empire of Steel

PRESS RELEASE Nov 10, 2017  Stillfront's studio Babil Games launches Nida Harb 3: Empire of Steel.   Babil Games, a studio in Stillfront Group, today launches Nida Harb 3: Empire of Steel on Android. iOS will follow shortly. This is the third instalment of the highly successful "Nida Harb" franchise. Nida Harb 3: Empire of Steel is an engaging mobile MMO-RTS (Massively multiplayer online real-time strategy game). As its predecessors, the game is set with a modern warfare theme, where players are given their own command of a military base to build and train massive armies in a quest

Tele2 IoT partners with Uniti to enable Uniti’s electric car journey

Uniti Sweden AB (publ) and Tele2 IoT  have signed a collaboration partnership agreement, where Tele2 IoT will provide connectivity, platforms and advisory services essential for Uniti’s electric car journey.Uniti is a Swedish company developing an electric city car. The car is optimized for high performance and agility in urban environments, with a user experience that replaces “press and pull” with “touch and swipe”. Holistic safety, sustainability, and scalability in manufacturing are the primary focus areas, enabled by the recyclable carbon fibre body and organic composite interior.

Receipt of payment for KRI oil exports

10 November 2017 Genel Energy plc Receipt of payment for KRI oil exports from Tawke and Taq Taq PSCs Genel Energy plc ('Genel' or 'the Company') is pleased to announce the receipt of payments from the Kurdistan Regional Government ('KRG') for oil sales during August 2017 from the Tawke and Taq Taq PSCs. Genel's net share of the payments is $16.86 million. Combined with the payment for the September override received earlier this week, this brings the total November 2017 net receipts to $23.27 million. DNO ASA, as operator of the Tawke PSC, has announced the receipt of $46.53

INTERIM REPORT 1 JANUARY-30 SEPTEMBER 2017

Third quarter (1 July-30 September 2017) · Net sales for the quarter amounted to MSEK 42 (77). · Operating profit before depreciation and amortisation (EBITDA) was MSEK 19 (21), of which associates had an impact of MSEK 0 (0) on the Group. Operating cash flow was MSEK 53 (70). · A decision was made to recognise impairment of MSEK 152 (0) on the company’s assets in relation to Own wind power operations and Wind power development. · Underlying EBIT (before impairment) was MSEK -1 (-1). Due to impairment, recognised EBIT was MSEK -153 (-1). · Loss before tax was MSEK -21 (-22)

Advania Sweden awarded with Microsoft Gold Partner Status x 10!

Andreas Slånemyr, Partner Manager for Microsoft at Advania, announces that Advania achieved Microsoft Gold Partner status within ten areas of expertise.Andreas Slånemyr, Partner Manager for Microsoft at Advania, announces that Advania achieved Microsoft Gold Partner status within ten areas of expertise. This is a prestigious award for Advania, since Microsoft is a significant supplier. It further consolidates the leading expertise within Advania, as well as the good outcome of completed assignments. Microsoft Partner Manager, Andreas Slånemyr states that:”Advania now goes to

New clinical study shows fewer adverse events with Bactiguard’s central venous catheter compared to a standard central venous catheter

A recently published clinical study* conducted at the Karolinska University Hospital in Sweden shows that Bactiguard’s infection prevention central venous catheter – BIP CVC had significantly fewer adverse events compared to a standard uncoated CVC. The study also shows that Bactiguard's noble metal alloy does not expose patients or the environment to any risks in blood applications.“This study confirms that the Bactiguard coating is durable and safe for patients also in blood applications and it shows promising results when it comes to reducing device related complications such as sepsis

Attendo's report for the third quarter 2017: More new openings – now over 10 000 beds in own operations

Attendo had a record number of openings during the third quarter, primarily related to nursing homes. In total 720 new beds were added, bringing the number of beds to 10,378 in own operations. Profit for the third quarter was in line with the corresponding quarter of 2016, but the margin was slightly lower.Comments by Henrik Borelius, CEO For the sixth consecutive quarter Attendo increased the number of beds under construction in own operations. This provides a foundation for continued stable growth. Attendo opened a record number of new homes and now has more than 10,000 beds in own

Announcement of managers' transactions: Grevermond Investments Ltd has purchased shares in Caverion Corporation on November 7, 2017

Caverion Corporation Stock exchange release November 10, 2017 at 9.00 a.m. EETAnnouncement of managers' transactions: Grevermond Investments Ltd has purchased shares in Caverion Corporation on November 7, 2017 Person subject to the notification requirement Name: Grevermond Investments Ltd Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Rosenlew Michael Position: Member of the Board Issuer: Caverion Oyj LEI: 7437007ECQWVPCJIS695 Notification type: INITIAL NOTIFICATION Reference number:

Finnair raises its guidance for comparable operating result and specifies its revenue forecast

Finnair Plc               Stock Exchange Release                   10 November 2017 at 9:00 am Finnair raises its guidance for its 2017 comparable operating result as passenger and cargo traffic sales have developed better than forecasted. Finnair also specifies its revenue forecast for 2017. New guidance Finnair estimates that in 2017 its capacity will grow approximately 9 per cent. Full-year revenue is expected to grow slightly faster than capacity. Finnair expects its comparable operating result for 2017 to exceed 155 million euro (2016: 55 million euro).  Previous

Interim Report

January 1 – September 30, 2017The third quarter in figures · Net sales amounted to TSEK 1,172 (1,580). · The loss after tax amounted to TSEK 8,810 (12,395). · The loss per share amounted to SEK 1.06 (1.50). · The cash flow from current operations was negative in the amount of TSEK 9,796 (10,459). · The gross margin in the period was 56.8 (44.6)%. · Electrode sales in volume grew in total by 9% and reached 3,440 (3,168) units. Repeat sales of electrodes grew by 42%. The first 9 months in figures · Net sales amounted to TSEK 4,973 (4,501). · The loss after tax

Nynas reports third quarter 2017

Sales volumes increased with 10 per cent in the third quarter. The operating result (EBITDA) amounted to SEK 311 million (541), negatively impacted by a weaker USD and sourcing limitations primarily in the Americas.“The third quarter was disappointing for Nynas with financial performance below expectations and previous year even though sales continued to develop positively,” commented Gert Wendroth, President and CEO of Nynas AB. THIRD QUARTER SUMMARY · Total product sales volumes increased by 10 per cent compared to the third quarter 2016. · Net sales increased to SEK 4,538

INVITATION TO Q3 2017 PRESENTATION

Techstep ASA will release its third quarter results on Friday 17 November at 7.00 am CET. The quarterly report and presentation will be made available on the company’s website www.techstepasa.no and www.newsweb.no. CEO Gaute Engbakk and CFO Marius Drefvelin will present the company’s results at 9:00 am CET at SpareBank 1 Markets, Olav V’s gate 5, in Oslo. The presentation will be given in Norwegian, with supporting material in English. The Q3 presentation can also be followed through live audio webcast. Webcast – audio and slide presentationPlease join the Q3 2017 results webcast

Herantis Pharma's Manager's Transactions

Herantis Pharma's Manager's Transactions Herantis Pharma PlcCompany release 10 Nov 2017 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Mattila, Pekka Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20171109210453_4 ____________________________________________ Transaction date: 2017-11-09 Venue: FIRST NORTH FINLAND (

Herantis Pharma's Manager's Transactions

Herantis Pharma's Manager's Transactions Herantis Pharma PlcCompany release 10 Nov 2017 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Wuite, Frans Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20171109211444_2 ____________________________________________ Transaction date: 2017-11-09 Venue: FIRST NORTH FINLAND (FNFI)

Herantis Pharma's Manager's Transactions

Herantis Pharma's Manager's Transactions Herantis Pharma PlcCompany release 10 Nov 2017 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Simula, Pekka Position: Chief Executive Officer Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20171109211640_5 ____________________________________________ Transaction date: 2017-11-09 Venue: FIRST NORTH FINLAND (FNFI)

Herantis Pharma's Manager's Transactions

Herantis Pharma's Manager's Transactions Herantis Pharma PlcCompany release 10 Nov 2017 at 9:00 am Herantis Pharma Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Veromaa, Timo Position: Member of the Board/Deputy member Issuer: Herantis Pharma Oyj LEI: 743700W4CQVYAT3WKK38 Notification type: INITIAL NOTIFICATION Reference number: 743700W4CQVYAT3WKK38_20171109211633_2 ____________________________________________ Transaction date: 2017-11-09 Venue: FIRST NORTH FINLAND (FNFI)

Elekta MR-linac functionality and CE mark update (Correction)

STOCKHOLM, November 10, 2017 – Elekta (EKTA-B.ST) has decided to add additional functional imaging capabilities to its MR-linac (Unity) and to spend more time on validating its linac control system in order to offer clinicians the unparalleled opportunities of its high field strength from the first release. Consequently, CE mark for Unity is currently expected during the first half of 2018 instead of the end of 2017.During 2017, Elekta successfully unveiled Unity in both Europe and the U.S. A first-in-man-study at the University of Utrecht and studies at other university hospitals confirmed

There are no items matching the current filter
There are no more items matching the current filter
Back to top